Current status of stem cell mobilization: Review

Research output: Contribution to journalReview article

102 Citations (Scopus)

Abstract

New advances in effective mobilization of peripheral blood stem cells have permitted a greater proportion of patients to benefit from autologous stem cell transplantation. In this review, the relative merits of peripheral blood and mobilized bone marrow are discussed. All available agents are reviewed. A critical assessment of the appropriate dosing and frequency of available growth factors is undertaken, and the most commonly used chemotherapy plus growth factor combinations are covered. Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor.

Original languageEnglish (US)
Pages (from-to)647-662
Number of pages16
JournalBritish Journal of Haematology
Volume150
Issue number6
DOIs
StatePublished - Sep 1 2010

Fingerprint

Hematopoietic Stem Cell Mobilization
Intercellular Signaling Peptides and Proteins
Stem Cell Transplantation
Bone Marrow
Drug Therapy
Peripheral Blood Stem Cells
JM 3100

Keywords

  • growth factors
  • mobilization
  • multiple myeloma
  • non-Hodgkin lymphoma
  • stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Current status of stem cell mobilization : Review. / Gertz, Morie.

In: British Journal of Haematology, Vol. 150, No. 6, 01.09.2010, p. 647-662.

Research output: Contribution to journalReview article

@article{077a483d07de4391a4b3a72b21da9489,
title = "Current status of stem cell mobilization: Review",
abstract = "New advances in effective mobilization of peripheral blood stem cells have permitted a greater proportion of patients to benefit from autologous stem cell transplantation. In this review, the relative merits of peripheral blood and mobilized bone marrow are discussed. All available agents are reviewed. A critical assessment of the appropriate dosing and frequency of available growth factors is undertaken, and the most commonly used chemotherapy plus growth factor combinations are covered. Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor.",
keywords = "growth factors, mobilization, multiple myeloma, non-Hodgkin lymphoma, stem cell transplantation",
author = "Morie Gertz",
year = "2010",
month = "9",
day = "1",
doi = "10.1111/j.1365-2141.2010.08313.x",
language = "English (US)",
volume = "150",
pages = "647--662",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Current status of stem cell mobilization

T2 - Review

AU - Gertz, Morie

PY - 2010/9/1

Y1 - 2010/9/1

N2 - New advances in effective mobilization of peripheral blood stem cells have permitted a greater proportion of patients to benefit from autologous stem cell transplantation. In this review, the relative merits of peripheral blood and mobilized bone marrow are discussed. All available agents are reviewed. A critical assessment of the appropriate dosing and frequency of available growth factors is undertaken, and the most commonly used chemotherapy plus growth factor combinations are covered. Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor.

AB - New advances in effective mobilization of peripheral blood stem cells have permitted a greater proportion of patients to benefit from autologous stem cell transplantation. In this review, the relative merits of peripheral blood and mobilized bone marrow are discussed. All available agents are reviewed. A critical assessment of the appropriate dosing and frequency of available growth factors is undertaken, and the most commonly used chemotherapy plus growth factor combinations are covered. Specific recommendations for patients who are poor mobilizers are dealt with including the role of plerixafor.

KW - growth factors

KW - mobilization

KW - multiple myeloma

KW - non-Hodgkin lymphoma

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=77956330290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956330290&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08313.x

DO - 10.1111/j.1365-2141.2010.08313.x

M3 - Review article

C2 - 20636438

AN - SCOPUS:77956330290

VL - 150

SP - 647

EP - 662

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -